P Borchmann
Overview
Explore the profile of P Borchmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
313
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brockelmann P, Muller H, Fuchs M, Gillessen S, Eichenauer D, Borchmann S, et al.
Ann Oncol
. 2024 Dec;
PMID: 39706337
Background: This study aimed to evaluate the correlation between progression-free (PFS) and overall survival (OS) after first-line treatment of classical Hodgkin lymphoma (HL) and to assess the potential of PFS...
2.
Ferdinandus J, Muller H, Damaschin C, Jacob A, Meissner J, Krasniqi F, et al.
Ann Oncol
. 2023 Dec;
35(3):276-284.
PMID: 38061428
Background: Persisting cancer-related fatigue impairs health-related quality of life (HRQoL) and social reintegration in patients with Hodgkin's lymphoma (HL). The GHSG HD18 trial established treatment de-escalation for advanced-stage HL guided...
3.
Balke-Want H, Borchmann P
Internist (Berl)
. 2021 Jun;
62(6):589-596.
PMID: 34152469
Following the first demonstration of efficacy of anti-CD19-directed chimeric antigen receptor (CAR) T cells in a patient with relapsed chronic lymphocytic leukemia (CLL) in 2011, pivotal studies for this innovative...
4.
Eichenauer D, Kreissl S, Buhnen I, Baues C, Kobe C, van Heek L, et al.
Ann Oncol
. 2021 Mar;
32(6):807-810.
PMID: 33667668
No abstract available.
5.
Behringer K, Thielen I, Mueller H, Goergen H, Eibl A, Rosenbrock J, et al.
Ann Oncol
. 2020 Jun;
31(8):1093.
PMID: 32553542
No abstract available.
6.
Borchmann S, Muller H, Hude I, Fuchs M, Borchmann P, Engert A
Ann Oncol
. 2019 May;
30(8):1329-1334.
PMID: 31132094
Background: The prognosis of Hodgkin lymphoma (HL) is excellent rendering research into treatment complications highly important. An important complication of cancer and its treatment is thrombosis. Thrombotic events are regularly...
7.
Voltin C, Goergen H, Baues C, Fuchs M, Mettler J, Kreissl S, et al.
Ann Oncol
. 2018 Jul;
29(9):1926-1931.
PMID: 30010775
Background: Bone marrow (BM) involvement defines advanced-stage Hodgkin lymphoma and thus has impact on the assignment to treatment. Our aim was to evaluate whether the established BM biopsy may be...
8.
Brockelmann P, Muller H, Casasnovas O, Hutchings M, von Tresckow B, Jurgens M, et al.
Ann Oncol
. 2017 Mar;
28(6):1352-1358.
PMID: 28327958
Background: Novel agents are changing the treatment of relapsed or refractory Hodgkin lymphoma (HL). Nevertheless, high-dose chemotherapy and autologous stem-cell transplantation (ASCT) are considered standard of care in eligible patients....
9.
Eichenauer D, Goergen H, Plutschow A, Wongso D, Behringer K, Kreissl S, et al.
Leukemia
. 2015 Nov;
30(6):1425-7.
PMID: 26585412
No abstract available.
10.
Kobe C, Kuhnert G, Haverkamp H, Fuchs M, Kahraman D, Eich H, et al.
Nuklearmedizin
. 2015 Sep;
54(6):241-6.
PMID: 26388152
Unlabelled: The aim was to analyze the degree of agreement between the central review panel and the local PET interpretation within the HD15 trial and its impact on subsequent treatment...